NeurologyLive Friday 5 — September 4, 2020

September 4, 2020

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending September 4, 2020.

Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: AMX0035 Slows Functional Decline in ALS in Phase 2/3

Data from the CENTAUR trial showed that the monthly rate of decline measured by ALSFR-S was 0.42 points slower for patients treated with the combination agent AMX0035.

2: Closing the Treatment Gap in Progressive MS

New biomarkers of disease activity may help better vet investigational therapies aimed at slowing the insidious neurodegeneration seen in primary progressive multiple sclerosis.

3: Marwan Sabbagh, MD: Observations From AAIC 2020

The director of the Lou Ruvo Center for Brain Health and neurologist at Cleveland Clinic detailed the state of Alzheimer disease and what research was top of mind at AAIC 2020.

4: Peer Exchange: The Future of Treating Multiple Sclerosis

Fred D. Lublin, MD; Sven Meuth, MD, PhD; Patricia Coyle, MD; and Wallace Brownlee, MBChB, PhD, FRACP, offer insight into how the treatment of MS will evolve in the coming years.

5: Lara Jehi, MD: Raising Awareness of the Benefits of Epilepsy Surgery

The chief research officer and epilepsy specialist at Cleveland Clinic detailed the reasons why epilepsy surgery is not utilized as often as it should, and her efforts to raise awareness.